Search research articles
Contact Us
Filters
Showing results (71-80 of 104) with videos related to
Page
of 11
Sort By:
Contact Dermatitis
|
June 27, 2002
Patch tests with thiurams at 0.25% pet. and 1% pet. are of equal diagnostic value
Johannes Geier, Peter J Frosch, Axel Schnuch, et al.
Melanoma Research
|
November 14, 2023
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS
Katharina C Kähler, Dirk Debus, Gaston Schley, et al.
The Lancet. Oncology
|
May 11, 2016
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Inflammatory Bowel Diseases
|
January 9, 2009
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study
Maria T Abreu, Christian von Tirpitz, Robert Hardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
November 17, 2025
S1 guideline for imaging diagnostics for skin diseases
Maximilian Deußing, Sandra Schuh, Janis Thamm, et al.
Cancers
|
November 26, 2022
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
Maximilian Haist, Henner Stege, Berenice Mareen Lang, et al.
Oncotarget
|
November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
Selma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 104) with videos related to
Sort By:
Page
of 11
Contact Dermatitis
|
June 27, 2002
Patch tests with thiurams at 0.25% pet. and 1% pet. are of equal diagnostic value
Johannes Geier, Peter J Frosch, Axel Schnuch, et al.
Melanoma Research
|
November 14, 2023
Effectiveness, safety and utilization of cobimetinib and vemurafenib in patients with BRAF V600 mutant melanoma with and without cerebral metastasis under real-world conditions in Germany: the non-interventional study coveNIS
Katharina C Kähler, Dirk Debus, Gaston Schley, et al.
The Lancet. Oncology
|
May 11, 2016
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Inflammatory Bowel Diseases
|
January 9, 2009
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study
Maria T Abreu, Christian von Tirpitz, Robert Hardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
Ulrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2009
Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma
Axel Hauschild, Michael Weichenthal, Knuth Rass, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
|
November 17, 2025
S1 guideline for imaging diagnostics for skin diseases
Maximilian Deußing, Sandra Schuh, Janis Thamm, et al.
Cancers
|
November 26, 2022
Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
Maximilian Haist, Henner Stege, Berenice Mareen Lang, et al.
Oncotarget
|
November 5, 2017
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
Selma Ugurel, Carmen Loquai, Patrick Terheyden, et al.
Page
of 11